Mahamaya Lifesciences Ltd
Submission of Press Release on Audited Financial Results for FY26
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 26 May 2026, 01:13 PM IST · BSE ID: c14348ee-4d36-49a0-97ef-76c57fb2998f
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's full-year revenue and profits increased significantly in FY26, with improved operating efficiency.
🤖 AI Summary
- Mahamaya Lifesciences Limited reported FY26 consolidated Revenue from Operations of 32,887.30 Lakhs, a 24.50% increase.
- Consolidated Net Profit (PAT) for FY26 stood at 1,652.33 Lakhs, marking a 28.97% increase.
- EBITDA Margin for FY26 improved by 60 BPS, reaching 10.42% compared to 9.82% in FY25.
- Diluted Earnings Per Share (EPS) for FY26 increased by 10.77% to 8.33.
- H2 FY26 Revenue from Operations was 16,580.93 Lakhs with an EBITDA Margin of 10.79%.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue From Operation (FY26)
32,887.30 Lakhs
24.50%
EBITDA (FY26)
3,425.88 Lakhs
32.06%
EBITDA Margin (FY26)
10.42%
60 BPS
PAT (FY26)
1,652.33 Lakhs
28.97%
PAT Margin (FY26)
5.02%
17 BPS
EPS (Diluted) (FY26)
8.33
10.77%
H2 FY26 Revenue From Operation
16,580.93 Lakhs
H2 FY26 EBITDA
1,789.84 Lakhs
H2 FY26 EBITDA Margin
10.79%
🏢 How This Affects the Company
The company's core business grew, reflected in a 24.50% increase in Revenue from Operations, indicating expansion in its agrochemical solutions market presence.
Consolidated Net Profit increased by 28.97% to 1,652.33 Lakhs, while EBITDA Margin improved by 60 BPS to 10.42%, signaling better profitability and operational efficiency. Profitability was impacted by approximately 411 Lakhs in adjustments.
Improved operational efficiencies are noted with EBITDA increasing to 3,425.88 Lakhs, and the company is focusing on expanding its sustainable and biological crop care portfolio.
The company absorbed approximately 411 Lakhs in accounting and listing-related adjustments, including unrealized forex loss of 264.16 Lakhs, which indicates exposure to foreign exchange fluctuations.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results press release.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, as reflected in the improved consolidated Net Profit of 1,652.33 Lakhs and Diluted EPS of 8.33 for FY26.
🔍
Management Signal
Management indicates a focus on expanding sustainable and biological crop care portfolios and strengthening market presence for long-term growth, as demonstrated by their FY26 performance.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q1 FY27 results — assess sustained revenue growth and margin performance.
Updates on expansion into bio-based crop care segments and market penetration.
Details on future capital expenditure for Dahej facility or R&D innovations.
LOW RISK
Financial results show healthy growth and improved margins despite one-off adjustments.
💡 Investor Takeaway
Mahamaya Lifesciences reported FY26 consolidated Revenue from Operations grew 24.50% to 32,887.30 Lakhs. Net Profit (PAT) increased 28.97% to 1,652.33 Lakhs, despite 411 Lakhs in accounting adjustments. EBITDA margin improved by 60 BPS to 10.42%.
⚖️ Strengths & Concerns
✅ Positives
- FY26 consolidated Revenue from Operations increased by 24.50% to 32,887.30 Lakhs, demonstrating business growth.
- FY26 consolidated Net Profit (PAT) grew by 28.97% to 1,652.33 Lakhs, alongside a 60 BPS improvement in EBITDA Margin to 10.42%.
⚠️ Concerns
- FY26 profitability was impacted by approximately 411 Lakhs in adjustments, including 264.16 Lakhs in unrealized forex loss.
- Exchange difference of 125.25 Lakhs and listing-related expenses of 21.57 Lakhs also reduced reported profitability for FY26.
📅 Company Track Record
Mahamaya Lifesciences Limited's FY26 consolidated net profit increased 28.97% to INR 1,652.33 Lakhs, following a similar disclosure on May 25, 2026, which reported the same increase and net profit figure.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Mahamaya Lifesciences' consolidated revenue for FY26?
Mahamaya Lifesciences reported consolidated Revenue from Operations of 32,887.30 Lakhs for FY26, an increase of 24.50% from FY25.
What was Mahamaya Lifesciences' consolidated net profit for FY26?
The consolidated Net Profit (PAT) for Mahamaya Lifesciences in FY26 was 1,652.33 Lakhs, which is a 28.97% increase compared to FY25.
How did Mahamaya Lifesciences' EBITDA Margin change in FY26?
Mahamaya Lifesciences' consolidated EBITDA Margin improved by 60 BPS, from 9.82% in FY25 to 10.42% in FY26.
What was Mahamaya Lifesciences' Diluted EPS for FY26?
The Diluted Earnings Per Share (EPS) for Mahamaya Lifesciences in FY26 was 8.33, showing a 10.77% increase from FY25.
What impact did adjustments have on Mahamaya Lifesciences' FY26 profitability?
Mahamaya Lifesciences' FY26 profitability was impacted by approximately 411 Lakhs in accounting and listing-related adjustments, including 264.16 Lakhs in unrealized forex loss.
Questions based on this BSE filing only. For information purposes.